An interventional study of Technology Based Intervention Group 1 and Technology Based Intervention Group 2 in Pain, Pain, Postoperative and Pain, Acute, sponsored by Vanessa Olbrecht. Completed at 1 site in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Vanessa Olbrecht · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.
Among the 2,886 studies in Pain with a site in United States, this one is the 1,036th largest by enrollment of the 2,564 interventional ones that give a count, is one of 94 that started in 2022, is one of 1,244 with no phase, and was the 2,254th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 21–65
Yale University · Sites in United States
Ages 30–75
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 6–17
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,886 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 417 · Phase 3 375 · Phase 4 372
First in 1957; this study’s year is marked. 94 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 66 across the 2,564 interventional studies, 99 across the 299 observational. Of the 2,228 that completed or were terminated, 1,051 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
671 of 2,886 have an industry lead sponsor. The 10 most frequent:
Vanessa Olbrecht is the lead sponsor of 2 studies on the registry; none are open to participants now.
Vanessa Olbrecht has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
172 of the studies in Pain with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05000281Phase 3Major Extremity Trauma Research ConsortiumEffect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures | 2026-11-30 |
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT07832552Phase 3Harrow IncA Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery | 2026-12 |
| NCT07276542Phase 3The Ketamine Research FoundationClinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved. | 2026-12-31 |
Add all 172 to your calendar (.ics) → With an account.
Among the 2,886 studies in Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To develop and refine a technology based treatment protocol for preoperative education and training and postoperative care in children and adolescents undergoing surgery.
This is a 2-phase study aimed to refine a perioperative treatment protocol for a technology-based intervention (Aim 1) and to understand whether technology-based interventions can be used to help treat pain in children following surgery (Aim 2). Patients will participate in only one phase of the study, and when patients are enrolled will determine what Phase of the study they are in.
In Phase 1, all patients will use the same technology, and no randomization will occur. Primary and secondary outcome measures of Aim 1 are assessed in Phase 1. Actual enrollment for Phase 1 was 23 patients.
In Phase 2, patients will be randomized to receive 1 of 2 technology-based interventions. The perioperative treatment protocol developed in Phase 1 (Aim 1) will be used in Phase 2 to assess the primary and secondary outcome measures of Aim 2. This phase is anticipated to enroll up to 70 participants.
This is not an FDA-regulated drug or device trial as the technology used in this study is categorized as a relaxation device by the FDA and considered "minimal risk", thus exempt from both NDE and IDE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Technology Based Intervention Group 1
Device: Technology Based Intervention Group 1
Device: Technology Based Intervention Group 2
In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
Aim 1 (Phase 1): Treatment Protocol Refinement
The goal of Aim 1 (Phase 1) of this study was to refine a study (treatment) protocol for the application of the VR technology in children and adolescents undergoing surgery anticipated to cause moderate to severe pain. The study protocol developed in Phase 1 would then be used as the study protocol to assess feasibility and acceptability of the VR technology in Phase 2. The outcome measure for this primary aim was the number of participants from which data was used to help design the study protocol.
Time frame: From two weeks before surgery up to 30 days after surgery
Aim 2 (Phase 2): Feasibility of Technology Intervention in Perioperative Patients
The primary goal of Aim 2 (Phase 2) of this study was to assess the feasibility of use of the VR technology in children and adolescents undergoing surgery anticipated to cause moderate to severe pain. We defined feasibility as the number of participants who were successfully enrolled and who completed study participation. Study participation was defined as completion of the final study visit.
Time frame: From two weeks before surgery until 30 days after surgery
Aim 1 (Phase 1): Preoperative Training Protocol
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome was measured as number of preoperative sessions completed by participants as a median, IQR.
Time frame: Up to two weeks before surgery
Aim 1 (Phase 1): Preoperative Training Protocol, Continued
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery as well as their ability to maintain target heart rate parameters during this preoperative training. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the session number when target heartrate parameters were first met for \> 50% of the session duration as measured using HeartMath reported as a median, IQR.
Time frame: Up to two weeks before surgery
Aim 1 (Phase 1): Preoperative Training Protocol, Continued
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery as well as their ability to maintain target heart rate parameters during this preoperative training. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the percentage of sessions in which patients maintained target heartrate parameters for \> 50% of the session duration (assessed using HeartMath), reported as a median, IQR.
Time frame: Up to two weeks before surgery
Aim 1 (Phase 1): Preoperative Training Protocol, Continued
One of the secondary outcomes in Aim 1 (Phase 1) of the study was to determine how long participants would use the VR technology during each session prior to surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. The outcome was measured as the session duration in minutes (mean, standard deviation).
Time frame: Up to two weeks before surgery
Aim 1 (Phase 1): Post-operative Session Protocol
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measured the number of postoperative sessions completed by participants as a median, IQR.
Time frame: Up to two weeks after surgery
Aim 1 (Phase 1): Post-operative Session Protocol, Continued
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery as well as their ability to maintain target heart rate parameters during these postoperative sessions. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the percentage of sessions in which patients maintained target heartrate parameters for \> 50% of the session duration (assessed using HeartMath), reported as a median, IQR.
Time frame: Up to two weeks after surgery
Aim 1 (Phase 1): Post-operative Session Protocol, Continued
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery as well as their ability to maintain target heart rate parameters during these postoperative sessions. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the session number when target heartrate parameters were first met for \> 50% of the session duration as measured using HeartMath reported as a median, IQR.
Time frame: Up to two weeks after surgery
Aim 1 (Phase 1): Postoperative Session Protocol, Continued
One of the secondary outcomes in Aim 1 (Phase 1) of the study was to determine how long participants would use the VR technology during each session after surgery. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. The outcome was measured as the session duration in minutes (mean, standard deviation).
Time frame: Up to two weeks after surgery
Aim 2 (Phase 2): Rate of Study Enrollment/Randomization
As a measure of feasibility in Phase 2 (Aim 2) of the study, we evaluated our ability to enroll participants in the study as defined as the number of patients who were successfully enrolled and agreed to be randomized to a treatment arm. A total of 70 patients were enrolled, and all 70 participants agreed to be randomized.
Time frame: Pre-intervention up to 2 weeks before surgery
Aim 2 (Phase 2): Rate of Study Retention
As a measure of feasibility in Phase 2 (Aim 2) of the study, we evaluated the ability to retain patients in the study. Retention was defined as the number of patients who completed the final study visit.
Time frame: From two weeks before surgery up to 30 days after surgery
Aim 2 (Phase 2): Rate of Treatment Adherence (Preoperative)
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of participants who participated in study activities both pre- and postoperatively. Treatment adherence was defined as the number of participants who completed at least one study activity in each respective time period (before and after surgery). This outcome measure assessed the number of participants who adhered to treatment preoperatively as measured by participant count.
Time frame: Up to 2 weeks before surgery
Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the number of days in which patients completed a technology session preoperatively, reported as median, IQR.
Time frame: Up to two weeks before surgery
Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the number of days in which participants completed a diary entry before surgery, as reported as a median, IQR.
Time frame: Up to two weeks before surgery
Aim 2 (Phase 2): Rate of Treatment Adherence (Post-operative)
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of participants who participated in study activities both pre- and postoperatively. Treatment adherence was defined as the number of participants who completed at least one study activity in each respective time period (before and after surgery). This outcome measure assessed the number of participants who adhered to treatment post-operatively as measured by participant count.
Time frame: Up to 30 days after surgery
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the total number of completed technology sessions after surgery by participants, reported as a median, IQR.
Time frame: Up to 30 days after surgery
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the total number of completed diary entries after surgery by participants, reported as a median, IQR.
Time frame: Up to 30 days after surgery
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the median number of days in which the assigned technology was used by participants after surgery, reported as a median, IQR.
Time frame: Up to 30 days
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the median number of technology sessions completed per day by participants after surgery, reported as median, IQR.
Time frame: Up to 30 days after surgery
Aim 2 (Phase 2): Treatment-specific Satisfaction
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of patients who completed the end-of-study surveys/questionnaires.
Time frame: Duration of study participation up to 30 days
Aim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection
One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one anxiety score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data from participants.
Time frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
Aim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection, Continued
One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of anxiety scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.
Time frame: Up to 2 weeks after surgery
Aim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection
One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one pain unpleasantness score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect data from participants
Time frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
Aim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection, Continued
One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of pain unpleasantness scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.
Time frame: Up to 2 weeks after surgery
Aim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection
One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one pain intensity score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect data from participants.
Time frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
Aim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection, Continued
One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of pain intensity scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.
Time frame: Up to 2 weeks after surgery
Aim 2 (Phase 2): Feasibility of Medication Use Data Collection
One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect opioid use postoperatively. In this measure, we evaluated the number of patients in which opioid use data was successfully collected after surgery.
Time frame: Post-intervention up to 7 days
| Milestone | Technology Based Intervention 1 (Aim 1/Phase 1) | Technology Based Intervention 1 (Aim 2/Phase 2) | Technology Based Intervention 2 (Aim 2/Phase 2) |
|---|---|---|---|
| Started | 23 | 39 | 31 |
| Completed | 23 | 35 | 30 |
| Not completed | 0 | 4 | 1 |
The goal of Aim 1 (Phase 1) of this study was to refine a study (treatment) protocol for the application of the VR technology in children and adolescents undergoing surgery anticipated to cause moderate to severe pain. The study protocol developed in Phase 1 would then be used as the study protocol to assess feasibility and acceptability of the VR technology in Phase 2. The outcome measure for this primary aim was the number of participants from which data was used to help design the study protocol.
| Participants | Technology Based Intervention 1 (Aim 1/Phase 1) |
|---|---|
| Aim 1 (Phase 1): Treatment Protocol Refinement | 23 (4 to 7) |
The primary goal of Aim 2 (Phase 2) of this study was to assess the feasibility of use of the VR technology in children and adolescents undergoing surgery anticipated to cause moderate to severe pain. We defined feasibility as the number of participants who were successfully enrolled and who completed study participation. Study participation was defined as completion of the final study visit.
| Participants | Technology Based Intervention 1 (Aim 2/Phase 2) | Technology Based Intervention 2 (Aim 2/Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Feasibility of Technology Intervention in Perioperative Patients | 35 | 30 |
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome was measured as number of preoperative sessions completed by participants as a median, IQR.
| Number of sessions | Technology Based Intervention 1 (Phase 1) |
|---|---|
| Aim 1 (Phase 1): Preoperative Training Protocol | 6 (4 to 7) |
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery as well as their ability to maintain target heart rate parameters during this preoperative training. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the session number when target heartrate parameters were first met for \> 50% of the session duration as measured using HeartMath reported as a median, IQR.
| Session number | Technology Based Intervention 1 (Phase 1) |
|---|---|
| Aim 1 (Phase 1): Preoperative Training Protocol, Continued | 1 (1 to 1) |
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery as well as their ability to maintain target heart rate parameters during this preoperative training. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the percentage of sessions in which patients maintained target heartrate parameters for \> 50% of the session duration (assessed using HeartMath), reported as a median, IQR.
| Percentage of Sessions | Technology Based Intervention 1 (Phase 1) |
|---|---|
| Aim 1 (Phase 1): Preoperative Training Protocol, Continued | 100 (86 to 100) |
One of the secondary outcomes in Aim 1 (Phase 1) of the study was to determine how long participants would use the VR technology during each session prior to surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. The outcome was measured as the session duration in minutes (mean, standard deviation).
| Minutes | Technology Based Intervention 1 (Phase 1) |
|---|---|
| Aim 1 (Phase 1): Preoperative Training Protocol, Continued | 9.6 ± 2.3 |
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measured the number of postoperative sessions completed by participants as a median, IQR.
| Number of sessions | Technology Based Intervention 1 (Phase 1) |
|---|---|
| Aim 1 (Phase 1): Post-operative Session Protocol | 2 (1 to 2.5) |
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery as well as their ability to maintain target heart rate parameters during these postoperative sessions. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the percentage of sessions in which patients maintained target heartrate parameters for \> 50% of the session duration (assessed using HeartMath), reported as a median, IQR.
| Percentage of sessions | Technology Based Intervention 1 (Phase 1) |
|---|---|
| Aim 1 (Phase 1): Post-operative Session Protocol, Continued | 83 (42 to 100) |
One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery as well as their ability to maintain target heart rate parameters during these postoperative sessions. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the session number when target heartrate parameters were first met for \> 50% of the session duration as measured using HeartMath reported as a median, IQR.
| Session number | Technology Based Intervention 1 (Phase 1) |
|---|---|
| Aim 1 (Phase 1): Post-operative Session Protocol, Continued | 1 (1 to 1) |
One of the secondary outcomes in Aim 1 (Phase 1) of the study was to determine how long participants would use the VR technology during each session after surgery. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. The outcome was measured as the session duration in minutes (mean, standard deviation).
| Minutes | Technology Based Intervention 1 (Phase 1) |
|---|---|
| Aim 1 (Phase 1): Postoperative Session Protocol, Continued | 9.5 ± 2.3 |
As a measure of feasibility in Phase 2 (Aim 2) of the study, we evaluated our ability to enroll participants in the study as defined as the number of patients who were successfully enrolled and agreed to be randomized to a treatment arm. A total of 70 patients were enrolled, and all 70 participants agreed to be randomized.
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Rate of Study Enrollment/Randomization | 39 | 31 |
As a measure of feasibility in Phase 2 (Aim 2) of the study, we evaluated the ability to retain patients in the study. Retention was defined as the number of patients who completed the final study visit.
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Rate of Study Retention | 35 | 30 |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of participants who participated in study activities both pre- and postoperatively. Treatment adherence was defined as the number of participants who completed at least one study activity in each respective time period (before and after surgery). This outcome measure assessed the number of participants who adhered to treatment preoperatively as measured by participant count.
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Rate of Treatment Adherence (Preoperative) | 35 | 29 |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the number of days in which patients completed a technology session preoperatively, reported as median, IQR.
| Days | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative) | 5 (4 to 5) | 4 (3 to 5) |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the number of days in which participants completed a diary entry before surgery, as reported as a median, IQR.
| Days | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative) | 5 (4 to 5) | 5 (3 to 5) |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of participants who participated in study activities both pre- and postoperatively. Treatment adherence was defined as the number of participants who completed at least one study activity in each respective time period (before and after surgery). This outcome measure assessed the number of participants who adhered to treatment post-operatively as measured by participant count.
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Rate of Treatment Adherence (Post-operative) | 34 | 26 |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the total number of completed technology sessions after surgery by participants, reported as a median, IQR.
| Technology sessions | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative) | 8 (5 to 13) | 7 (2 to 9) |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the total number of completed diary entries after surgery by participants, reported as a median, IQR.
| Diary entries | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative) | 11.5 (6 to 15) | 12.5 (5 to 16) |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the median number of days in which the assigned technology was used by participants after surgery, reported as a median, IQR.
| Days | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative) | 5 (4 to 5) | 4 (2 to 5) |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the median number of technology sessions completed per day by participants after surgery, reported as median, IQR.
| Technology sessions per day | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative) | 2 (1.6 to 2.6) | 2 (1.6 to 2.4) |
As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of patients who completed the end-of-study surveys/questionnaires.
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Treatment-specific Satisfaction | 35 | 30 |
One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one anxiety score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data from participants.
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Preoperative, immediately before session | 26 | 21 |
| Postoperative, immediately before session | 35 | 27 |
| Postoperative, immediately after session | 35 | 24 |
| Postoperative, 15 minutes after session | 35 | 24 |
| Postoperative, 30 minutes after session | 35 | 24 |
One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of anxiety scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.
| Number of anxiety scores reported | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Postoperative, immediately before session | 12 (6 to 16) | 12 (4 to 16) |
| Postoperative, immediately after session | 10 (6 to 15) | 8 (2 to 10) |
| Postoperative, 15 minutes after session | 10 (6 to 15) | 8 (2 to 12) |
| Postoperative, 30 minutes after session | 10 (6 to 15) | 8 (2 to 10) |
One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one pain unpleasantness score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect data from participants
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Preoperative, immediately before session | 26 | 21 |
| Postoperative, immediately before session | 35 | 27 |
| Postoperative, immediately after session | 35 | 24 |
| Postoperative, 15 minutes after session | 35 | 24 |
| Postoperative, 30 minutes after session | 35 | 24 |
One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of pain unpleasantness scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.
| # of pain unpleasantness scores reported | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Postoperative, immediately before session | 12 (6 to 16) | 12 (4 to 16) |
| Postoperative, immediately after session | 10 (6 to 15) | 8 (2 to 10) |
| Postoperative, 15 minutes after session | 10 (6 to 15) | 8 (2 to 10) |
| Postoperative, 30 minutes after session | 10 (6 to 15) | 8 (2 to 10) |
One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one pain intensity score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect data from participants.
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Preoperative, immediately before session | 26 | 21 |
| Postoperative, immediately before session | 35 | 27 |
| Postoperative, immediately after session | 35 | 24 |
| Postoperative, 15 minutes after session | 35 | 24 |
| Postoperative, 30 minutes after session | 35 | 24 |
One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of pain intensity scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.
| # of pain intensity scores reported | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Postoperative, immediately before session | 12 (6 to 16) | 12 (4 to 16) |
| Postoperative, immediately after session | 10 (6 to 15) | 8 (2 to 10) |
| Postoperative, 15 minutes after session | 10 (6 to 15) | 8 (2 to 10) |
| Postoperative, 30 minutes after session | 10 (6 to 15) | 8 (2 to 10) |
One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect opioid use postoperatively. In this measure, we evaluated the number of patients in which opioid use data was successfully collected after surgery.
| Participants | Technology Based Intervention 1 (Phase 2) | Technology Based Intervention 2 (Phase 2) |
|---|---|---|
| Aim 2 (Phase 2): Feasibility of Medication Use Data Collection | 35 | 30 |
Collected over 1 month. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Technology Based Intervention 1 (Phase 1) | 0/23 (0%) | 0/23 (0%) | 0/23 (0%) |
| Technology Based Intervention 1 (Phase 2) | 0/39 (0%) | 0/39 (0%) | 0/39 (0%) |
| Technology Based Intervention 2 (Phase 2) | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Age, Categorical(Participants) | Technology Based Intervention 1 (Aim 1/Phase 1) | Technology Based Intervention 1 (Aim 2/Phase 2) | Technology Based Intervention 2 (Aim 2/Phase 2) | Total |
|---|---|---|---|---|
| <=18 years | 23 | 39 | 31 | 93 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Technology Based Intervention 1 (Aim 1/Phase 1) | Technology Based Intervention 1 (Aim 2/Phase 2) | Technology Based Intervention 2 (Aim 2/Phase 2) | Total |
|---|---|---|---|---|
| Mean | 15.5 ± 1.8 | 16.2 ± 1.8 | 15.4 ± 1.9 | 15.9 ± 1.9 |
| Sex: Female, Male(Participants) | Technology Based Intervention 1 (Aim 1/Phase 1) | Technology Based Intervention 1 (Aim 2/Phase 2) | Technology Based Intervention 2 (Aim 2/Phase 2) | Total |
|---|---|---|---|---|
| Female | 16 | 18 | 23 | 57 |
| Male | 7 | 21 | 8 | 36 |
| Race (NIH/OMB)(Participants) | Technology Based Intervention 1 (Aim 1/Phase 1) | Technology Based Intervention 1 (Aim 2/Phase 2) | Technology Based Intervention 2 (Aim 2/Phase 2) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 3 | 10 |
| White | 19 | 30 | 26 | 75 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 2 | 2 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Technology Based Intervention 1 (Aim 1/Phase 1) | Technology Based Intervention 1 (Aim 2/Phase 2) | Technology Based Intervention 2 (Aim 2/Phase 2) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 2 | 5 |
| Not Hispanic or Latino | 22 | 36 | 29 | 87 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Technology Based Intervention 1 (Aim 1/Phase 1) | Technology Based Intervention 1 (Aim 2/Phase 2) | Technology Based Intervention 2 (Aim 2/Phase 2) | Total |
|---|---|---|---|---|
| United States | 23 | 39 | 31 | 93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — IPD will not be shared with the public, but aggregate data will be publicly available upon request.
Ran from Mar 2022 to primary completion in Aug 2025, 40 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 40 months is above that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanessa Olbrecht